Drug-eluting stents articles

TCT 2023 | ALIGN AR trial

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).  Primary end point was late lumen loss (LLL) at 12 months.  There were no significant differences between the groups. Mean patient age was 63, 75% were

Resultados del estudio COMPARE a 2 años: Balones cubiertos de Paclitaxel con bajas dosis vs altas dosis

Ultrathin Stents Shown Safe and Effective in Real World Patients

Ultrathin drug eluting stents (60 µm) had been shown beneficial vs. thin-strut stents in terms of target lesion failure (TLF) at 2, 3 and 5 years in randomized studies, but they had not been yet assessed in “real world” patients.  The BIOFLOW VII is a prospective, multicenter study including 556 “real world”patients with a total

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

Use of Drug-Coated Balloons in De Novo Lesions in Large Coronary Vessels

Drug-coated balloon (DCB) angioplasty is emerging as a novel treatment for coronary artery disease. Studies evaluating this strategy have demonstrated clinically non-inferior outcomes compared with those of drug-eluting stent (DES) implantation in patients with in-stent restenosis and de novo disease in small vessels. However, evidence for the use of DCBs in large coronary vessels is

stent-liberador-drogas-sirolimus-everolimus

EASTBOURNE Registry: Use of Sirolimus-Coated Balloons in Coronary Artery Disease

The introduction of drug coated balloons (DCB) has become an innovative therapeutic alternative to current treatments. Paclitaxel-coated balloons (PCB) have been used to treat in-stent restenosis (ISR) and also approach CAD in native arteries. More recently, sirolimus-coated balloons (SCB) are being looked at as part of pilot studies and smaller registries with preliminary results.  The

SOLACI-SBHCI 2023 | Vascular Access for Large Bore Introducers and Review on Arterial Sheaths – Dr. Guilherme Bernardi

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Guilherme Bernardi, entitled “Vascular Access for Large Bore Introducers and Review on Arterial Sheaths”

Abbott Vascular suspendió la venta de Absorb en todos los países

ABSORB IV – Improving Bioresorbable Scaffolds: A Long Road

5-year followup of bioresorbable scaffolds in selected and better prepared lesions (ABSORB IV).  Historically, when comparing previously used therapies, such as conventional balloon angioplasty (BA) against bare metal stent (BMS) and later against drug eluting stent (DES) implantation, we see significantly improved outcomes. These advances have shown reduced recoil and more effective restenosis inhibition, compared

Post PCI Functional Assessment for Focal Lesion and Stent Underexpansion Detection

The use of fractional flow reserve (FFR) and non-hyperemic pressure indices (NHPRs) have become essential for intermediate lesion revascularization.  A linear inverse correlation has been recently shown between the use of post PCI physiology and cardiovascular events at followup. However, its adoption has been limited so far, seeing the wide variety of algorithms used in

enfermedad carotídea y coronaria severa

5 Year Evolution of PCI vs CABG in Large Randomized Studies on Acute and Chronic Coronary Syndrome

Left main lesions in acute coronary syndrome (ACS) represent a major risk and, at present, the best revascularization strategy is a matter of debate. Though many studies and registries have excluded this group of patients, there is data on the pros and cons of both percutaneous coronary intervention (PCI) and cardiac artery bypass graft (CABG). 

¿Es frecuente el uso de IVUS para guiar la ATC?

Minimal Stent Area: New IVUS Parameter?

Intravascular Ultrasound (IVUS) has shown, in several studies, its great benefits for both restenosis and mortality reduction.   Even though several variables have been studied, so far minimal stent area (MSA) has been disregarded as important.  The OPTIVUS-Complex PCI looked at 961 patients with 1,957 lesions, and found 1.6% TLR incidence (30 lesions). There were no

synergy vs XIENCE

Diffuse Coronary Artery Disease: One-Year 48mm XIENCE Skypoint Outcomes

Long 48mm Stent XIENCE Skypoint in the treatment of diffuse CAD Long coronary artery lesions often involve complex decision making since they can be treated either with a long stent or with shorter overlapping stents. Both in registries and meta-analysis, the overlapping technique has been associated to increased target vessel revascularization and increased radioscopy time,

Resultado a 3 años luego de ATC con técnica de 2- stents vs Provisional stent por bifurcaciones complejas

Provisional Stenting vs. Culotte: 5-Year Results of EBC TWO

The optimal treatment of true bifurcation lesions not affecting the left main coronary artery is widely debated. Results from randomized studies have shown neutral or worse outcomes with the two-stent technique. Regarding these studies, researchers used first-generation stents and the secondary branches were small. The EBC TWO study compared the provisional stenting strategy against the

Top